Frost & Sullivan, in collaboration with industry partners such as Cytiva, released the 'In Vivo CAR-T Industry Blue Book'

Over the past decade, CAR-T therapy has made significant breakthroughs in blood tumors, demonstrating the great potential of engineered immune cell therapy. However, traditional ex vivo CAR-T still relies on personalized preparation, involving multiple steps such as cell collection, gene modification, amplification, quality control, transportation, and reinfusion. The treatment cycle is relatively long, and the manufacturing costs and supply chain complexity are high.

in vivo CAR-TThis provides new ideas to overcome the limitations of traditional CAR-T.As a cutting-edge direction integrating cell therapy, RNA drugs, targeted delivery, and genetic engineering, itinduces immune cells to express CAR through viral vectors or lipid nanoparticles, enabling “in vivo engineered” treatment,potentially facilitating CAR-T to move from personalized customization to a more standardized and platform-based development model.

Under this context,Frost & Sullivan(Frost & Sullivan, hereinafter referred to as “Frost & Sullivan”) in collaboration withCytivaand other industry partners has released the “In vivo CAR-T Industry Blue Book”.The Blue Book systematically outlines the development background, technical pathways, clinical translation, industrialization challenges, and future trends of in vivo CAR-T, aiming to provide systematic industry insights and research references for the industry, academia, investment institutions, and clinical fields.

Twelve leading industry companies have jointly released it, bringing together insights from dozens of top experts—the first Blue Book on in vivo CAR-T cell therapy is released, defining new development benchmarks for the industry.